The Latest Breaking News from Viking Therapeutics

Viking's Obesity Edge May Be Staying Power, Not Weight Loss

Viking Therapeutics shares jumped 36% after VK2735 maintenance data showed patients kept most weight loss on less frequent dosing, though Phase 3 results and commercial funding remain unresolved.

MarketBeat · Sep 23

VKTX Stock Soars as Viking Therapeutics Announces Positive GLP-1 Trial Results

Viking Therapeutics shares rally on promising Phase 2 data for its candidate weight-loss treatment. Here’s why caution is still warranted in buying VKTX stock today.

Barchart · Sep 22

This Hot Weight-Loss Drug Stock May Be a Surprise Challenger

The race to dominate the weight-loss drug market is heating up, and investors should start watching this one smaller player closely.

Barchart · May 14

What's Up With The Jump In Viking Therapeutics Stock?

Viking Therapeutics Inc (NASDAQ:VKTX) shares are trading higher on Thursday. The clinical-stage biopharmaceutical company seems to be benefitting from wider excitement in the obesity treatment area, as well as recent positive momentum after major clinical trial developments.

Benzinga · Dec 4, 2025

3 Weight-Loss Drug Stocks To Consider For 2026

The global weight loss drug market, perhaps ironically, is growing like gangbusters these days. Globally, it’s set to expand from $15 billion in 2024 to $150 billion by 2035, according to Morgan Stanley.

Benzinga · Nov 21, 2025

AMD, Oklo, AppLovin Corp, Viking Therapeutics And Novo Nordisk: Why These 5 Stocks Are On Investors' Radars Today

Major U.S. indices closed mixed on Tuesday, with the Dow Jones Industrial Average climbing 1.2% to 47,927.96 and the SP 500 inching up 0.2% to 6,846.61, while the tech-heavy Nasdaq slipped 0.25% to 23,468.30.

Benzinga · Nov 12, 2025

Why Is Viking Therapeutics Stock Rising Today?

Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX) are rising Thursday. The clinical-stage biopharmaceutical company reported third-quarter earnings and provided updates on clinical trials.

Benzinga · Oct 23, 2025

Jim Cramer Expects Palantir To Reach New All-Time High

Investor sentiment often swings with the ebb and flow of clinical trial results, technological advancements, and strategic corporate partnerships. In this volatile environment, market analysts and financial commentators provide crucial guidance to help navigate the complex landscape of investment opportunities.

Benzinga · Sep 5, 2025

Viking's 42% Plunge Splits Experts—A '$129 Strong Buy' Or 'Clearly Inferior' Drug?

Viking Therapeutics Inc. (NASDAQ:VKTX) saw its stock collapse by over 42% on Tuesday after data from its Phase 2 obesity pill trial disappointed investors, sparking a fierce debate between Wall Street bulls and critical biotech experts.

Benzinga · Aug 20, 2025

Market Bloodbath: Viking Therapeutics Stock Tanks After Obesity Pill Side Effects Trigger Mass Dropouts

Viking Therapeutics shares plunged 40% after trial data for its obesity pill, VK2735, revealed high dropout rates due to side effects, raising doubts about its competitiveness against rivals Eli Lilly and Novo Nordisk.

International Business Times UK · Aug 19, 2025